Progesterone Market Report 2026

The progesterone market size has grown rapidly in recent years. It will grow from $1.79 billion in 2025 to $2.06 billion in 2026 at a compound annual growth rate (CAGR) of 14.8%. The growth in the historic period can be attributed to limited availability of natural progesterone, reliance on branded formulations, growing awareness of menopausal therapies, increasing incidence of dysfunctional uterine bleeding, adoption of conventional oral contraceptives.

The progesterone market size is expected to see rapid growth in the next few years. It will grow to $3.54 billion in 2030 at a compound annual growth rate (CAGR) of 14.5%. The growth in the forecast period can be attributed to development of synthetic progestins and advanced delivery systems, rising demand for personalized hormone therapy, growth in fertility and contraceptive clinics, increasing research in endometrial cancer treatment, adoption of minimally invasive administration routes. Major trends in the forecast period include rising demand for natural progesterone formulations, growth in hormone replacement therapy (hrt) usage, increasing adoption of injectable and transdermal routes, expansion of contraceptive and fertility treatments, focus on personalized medicine and endometrial health.

The rising prevalence of hormonal disorders is anticipated to drive the growth of the progesterone market in the coming years. Hormonal disorders are medical conditions that arise from imbalances or dysfunctions within the body’s endocrine system, which is responsible for producing and regulating hormones that control essential functions such as metabolism, growth, reproduction, and mood. The growing occurrence of hormonal disorders is largely attributed to modern lifestyle factors, including unhealthy diets, persistent stress, physical inactivity, and exposure to environmental toxins. Progesterone plays a key role in managing hormonal disorders by helping restore hormonal balance, regulate menstrual cycles, and alleviate symptoms associated with estrogen dominance. It also supports the activity of other hormones, such as estrogen and cortisol, contributing to overall endocrine stability and helping manage conditions like polycystic ovary syndrome (PCOS) and premenstrual syndrome (PMS). For instance, in January 2025, according to the World Health Organization, a Switzerland-based intergovernmental organization, polycystic ovary syndrome was identified as a major public health concern and one of the most prevalent hormonal disorders among women of reproductive age, affecting an estimated 6-13% annually. Therefore, the increasing prevalence of hormonal disorders is fueling the growth of the progesterone market.

Major companies operating in the progesterone market are concentrating on the development of innovative formulations, such as soft vaginal capsules, to enhance patient adherence and improve drug absorption. Soft vaginal capsules are smooth, gel-based inserts intended for vaginal administration that deliver medication directly to the target area, supporting hormonal balance, treating conditions, and maintaining vaginal health. For example, in April 2024, Besins Healthcare (UK) Limited, a UK-based pharmaceutical manufacturing company, introduced Prometrium 400 mg soft vaginal capsules for the prevention of miscarriage in women experiencing early pregnancy bleeding with a history of recurrent miscarriage. This novel formulation is the first licensed product of its kind in the UK and is designed to improve treatment outcomes and patient compliance by providing a targeted, non-invasive delivery approach that enhances progesterone absorption at the site of action.

In October 2024, Audax Private Equity, a US-based private equity firm, acquired the clinical services business of Avantor, Inc. for an undisclosed amount. Through this acquisition, Audax aims to establish the business - now rebranded as Resonant Clinical Solutions - as an independent platform within the outsourced clinical trial services market, strengthening its service capabilities and leveraging established customer relationships. Avantor, Inc. is a US-based biotechnology company that specializes in supplying progesterone.

Major companies operating in the progesterone market are Pfizer Inc., Johnson & Johnson, Merck & Co Inc., Allergan plc, AbbVie Inc., Bayer AG, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd, Gedeon Richter Plc., Dr. Reddy’s Laboratories Ltd., Cipla Limited, Cadila Pharmaceuticals Ltd., Aspen Pharmacare, BIOCON Ltd., Zhejiang Xianju Pharmaceutical Co. Ltd., Beximco Pharmaceuticals Ltd., Besins healthcare (UK) limited., Sichuan Deebio Pharmaceutical Co. Ltd., Changzhou Siyao Pharmaceuticals Co. Ltd., Shanghai Shyndec Pharmaceutical Co. Ltd.

North America was the largest region in the progesterone market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the progesterone market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the progesterone market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the progesterone market by increasing costs of imported raw materials and pharmaceutical intermediates, particularly affecting natural progesterone extraction and synthetic progestin manufacturing. Segments such as injectable formulations and transdermal products are most impacted, with regions like Europe and Asia-Pacific facing notable import duties. This has led to higher production costs and adjustments in supply chains. On the positive side, tariffs encourage local production, innovation in cost-efficient formulations, and development of domestic hormone therapy manufacturing capacities.

The progesterone market research report is one of a series of new reports that provides progesterone market statistics, including progesterone industry global market size, regional shares, competitors with a progesterone market share, detailed progesterone market segments, market trends and opportunities, and any further data you may need to thrive in the progesterone industry. This progesterone market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Progesterone is a steroid hormone that plays a key role in the menstrual cycle, pregnancy, and embryonic development in humans and other species. It prepares the endometrium, or uterine lining, for the possible implantation of a fertilized egg, supports early pregnancy, and suppresses further ovulation during pregnancy. Progesterone is also widely used in hormone replacement therapy and in birth control pills, where it is present in synthetic forms known as progestins.

The main product types of progesterone include natural progesterone and synthetic progesterone. Natural progesterone, often described as bioidentical progesterone, is a hormone sourced from plants such as soybeans or wild yams. These products are available in both branded and generic versions and can be administered through several routes, including injectable, oral, transdermal, and other methods. Progesterone is used for a variety of applications, including menopause management, contraception, dysfunctional uterine bleeding, hyperplastic precursor lesions, endometrial cancer, and other indications. The primary end users include hospitals, clinics, research institutions, and other healthcare settings.

The progesterone market consists of sales of oral capsules, vaginal gels, creams, injections, and intrauterine devices. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.